Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevoflurane MAC comparison in normal patients, mild cognitive impairment, and mild cognitive impairment with sleep disorders
ChiCTR2400082114Phase 4Recruiting
- Sponsor
- Cangzhou Central Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sevoflurane in Mild Cognitive Impairment (MCI) (3 arms), sponsored by Cangzhou Central Hospital. Primary endpoint: Kinesthetic reaction. Started Mar 2024; status: recruiting.
02
Drugs
sevoflurane
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on ChiCTR2400082114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082114.